pharmaceutical daily news

Alvogen and Prestige BioPharma have entered into a deal for the exclusive partnership and supply for the commercialization of Prestige BioPharma´s Trastuzumab biosimilar Hervelous in Central and Eastern Europe.

AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the Japanese Ministry of Health, Labour and Welfare approved Imfinzi (durvalumab) as maintenance therapy after definitive chemoradiation therapy (CRT) in locally-advanced (Stage III), unresectable non-small cell lung cancer (NSCLC).

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Cablivi (caplacizumab) in Europe for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood-clotting disorder, which can be made available to patients through Sanofi Genzyme.

Novartis on Friday said it intends to spinoff Alcon, its eye care division, into a separately-traded standalone company, which would enable Novartis and Alcon to focus fully on their respective growth strategies.

Sanofi and Advent International have finished negotiations for the acquisition of Zentiva, Sanofi’s European generics business, by Advent and the companies have signed a Share Purchase Agreement worth €1.9 billion (enterprise value).

Novartis and the European Migraine and Headache Alliance (EMHA) Wednesday presented initial findings from the largest global migraine patient study to date, involving over 11,000 people from 31 countries, reveal that migraine cuts work productivity by half, as 60% of employed respondents on average missed almost a full working week

AstraZeneca and Merck’s Phase III SOLO-1 trial of Lynparza (olaparib) tablets, for women with BRCA-mutated (BRCAm) advanced ovarian cancer treated 1st-line with Lynparza maintenance therapy, brought good results.

Symcel said Wednesday it has appointed two new board members; Erik Walldén and Stefan Löfås, who are expected to play a key role in bolstering the full execution of the company’s corporate strategy to grow business in the research market and develop much needed solutions for clinical diagnostics.